796 results on '"HEIST, REBECCA"'
Search Results
52. Supplementary Tables S3-S8 from Genomic and Functional Fidelity of Small Cell Lung Cancer Patient-Derived Xenografts
53. Data from Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer
54. Supplementary Figures 1-11 from Genomic and Functional Fidelity of Small Cell Lung Cancer Patient-Derived Xenografts
55. Supplementary Tables 4-5 from Combination Olaparib and Temozolomide in Relapsed Small-Cell Lung Cancer
56. Supplementary Methods from Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer
57. Clinical Trial Protocol from Combination Olaparib and Temozolomide in Relapsed Small-Cell Lung Cancer
58. Supplementary Tables S1 - S14 from Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer
59. Supplementary Data from Combination Olaparib and Temozolomide in Relapsed Small-Cell Lung Cancer
60. Supplementary Figures from Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer
61. Supplementary Figures S1 - S9 from Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer
62. Data from Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer
63. New Therapies on the Horizon
64. Supplementary Data from Results and Molecular Correlates from a Pilot Study of Neoadjuvant Induction FOLFIRINOX Followed by Chemoradiation and Surgery for Gastroesophageal Adenocarcinomas
65. Supplementary Table 2 from Polymorphisms in MicroRNAs Are Associated with Survival in Non–Small Cell Lung Cancer
66. Supplementary Table 1 from Polymorphisms in MicroRNAs Are Associated with Survival in Non–Small Cell Lung Cancer
67. Supplementary Figure 4 from Polymorphisms in MicroRNAs Are Associated with Survival in Non–Small Cell Lung Cancer
68. Supplementary Figure Legend from Differential Outcomes in Codon 12/13 and Codon 61 NRAS-Mutated Cancers in the Phase II NCI-MATCH Trial of Binimetinib in Patients with NRAS-Mutated Tumors
69. Supplementary Table 1 and Figures 1 - 6 from Genome-Wide Association Study of Prognosis in Advanced Non–Small Cell Lung Cancer Patients Receiving Platinum-Based Chemotherapy
70. Supplemental Figures from Differential Outcomes in Codon 12/13 and Codon 61 NRAS-Mutated Cancers in the Phase II NCI-MATCH Trial of Binimetinib in Patients with NRAS-Mutated Tumors
71. Supplementary Figure 1 from Polymorphisms in MicroRNAs Are Associated with Survival in Non–Small Cell Lung Cancer
72. Supplementary Figure 2 from Polymorphisms in MicroRNAs Are Associated with Survival in Non–Small Cell Lung Cancer
73. Data from Polymorphisms in MicroRNAs Are Associated with Survival in Non–Small Cell Lung Cancer
74. Supplementary Figure 3 from Polymorphisms in MicroRNAs Are Associated with Survival in Non–Small Cell Lung Cancer
75. Supplementary Figure S1 from Therapy of Small Cell Lung Cancer (SCLC) with a Topoisomerase-I–inhibiting Antibody–Drug Conjugate (ADC) Targeting Trop-2, Sacituzumab Govitecan
76. Supplemental Table from Differential Outcomes in Codon 12/13 and Codon 61 NRAS-Mutated Cancers in the Phase II NCI-MATCH Trial of Binimetinib in Patients with NRAS-Mutated Tumors
77. Supplementary Table S1 from Therapy of Small Cell Lung Cancer (SCLC) with a Topoisomerase-I–inhibiting Antibody–Drug Conjugate (ADC) Targeting Trop-2, Sacituzumab Govitecan
78. Data from Failure to Induce Apoptosis via BCL-2 Family Proteins Underlies Lack of Efficacy of Combined MEK and PI3K Inhibitors for KRAS-Mutant Lung Cancers
79. Supplementary Figures 1 - 19 from Failure to Induce Apoptosis via BCL-2 Family Proteins Underlies Lack of Efficacy of Combined MEK and PI3K Inhibitors for KRAS-Mutant Lung Cancers
80. Supplementary Materials and Methods from Failure to Induce Apoptosis via BCL-2 Family Proteins Underlies Lack of Efficacy of Combined MEK and PI3K Inhibitors for KRAS-Mutant Lung Cancers
81. Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein–Expressing Non–Small-Cell Lung Cancer
82. First-in-Human, Phase I Dose-Escalation and Dose-Expansion Study of Trophoblast Cell-Surface Antigen 2–Directed Antibody-Drug Conjugate Datopotamab Deruxtecan in Non–Small-Cell Lung Cancer: TROPION-PanTumor01.
83. Intracranial Efficacy of Adagrasib in Patients From the KRYSTAL-1 Trial With KRAS G12C -Mutated Non–Small-Cell Lung Cancer Who Have Untreated CNS Metastases.
84. ANtiangiogenic Second-line Lung cancer Meta-Analysis on individual patient data in non-small cell lung cancer: ANSELMA
85. Molecularly Targeted Therapies in Non–Small-Cell Lung Cancer Annual Update 2014
86. LKB1 loss rewires JNK-induced apoptotic protein dynamics through NUAKs and sensitizes KRAS-mutant NSCLC to combined KRASG12C + MCL-1 blockade
87. Phase I single dose, two-period and two-sequence cross-over trial to evaluate the relative bioavailability of two oral pimasertib formulations in advanced cancer patients
88. Reply to Ciccolini et al. : Using mathematical modeling to predict response to antiangiogenic therapy in cancer patients
89. Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer
90. LKB1 loss rewires JNK-induced apoptotic protein dynamics through NUAKs and sensitizes KRAS-mutant NSCLC to combined KRASG12C + MCL-1 blockade
91. Brief Report: Safety and Antitumor Activity of Alectinib Plus Atezolizumab From a Phase 1b Study in Advanced ALK-Positive NSCLC
92. The Prognostic Impact of KRAS, Its Codon and Amino Acid Specific Mutations, on Survival in Resected Stage I Lung Adenocarcinoma
93. CALGB 30704 (Alliance): A Randomized Phase II Study to Assess the Efficacy of Pemetrexed or Sunitinib or Pemetrexed Plus Sunitinib in the Second-Line Treatment of Advanced Non–Small-Cell Lung Cancer
94. Implementation and Clinical Adoption of Precision Oncology Workflows Across a Healthcare Network
95. Adagrasib in Non–Small-Cell Lung Cancer Harboring a KRASG12C Mutation
96. A Phase 2 Study of Lorlatinib in Patients With ROS1-Rearranged Lung Cancer With Brain-Only Progression on Crizotinib
97. O13-6 Japanese subgroup analysis of datopotamab deruxtecan in NSCLC cohort of TROPION-PanTumor01, a phase 1 study
98. Abstract CT033: KontRASt-01: A phase Ib/II, dose-escalation study of JDQ443 in patients (pts) with advanced, KRAS G12C-mutated solid tumors
99. Abstract CT197: Phase Ib study of LXH254 + trametinib (TMT) in patients (pts) with NRAS-mutant melanoma
100. Abstract CT202: A first-in-human phase 1 study of LY3537982, a novel, highly selective and potent KRAS G12C inhibitor in patients with KRAS G12C mutant advanced solid tumors (trial in progress)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.